Quince Therapeutics, Inc. - Asset Resilience Ratio
Quince Therapeutics, Inc. (QNCX) has an Asset Resilience Ratio of 18.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Quince Therapeutics, Inc. (QNCX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Quince Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See what is Quince Therapeutics, Inc.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Quince Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Quince Therapeutics, Inc. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.84 Million | 18.05% |
| Total Liquid Assets | $19.84 Million | 18.05% |
Asset Resilience Insights
- Good Liquidity Position: Quince Therapeutics, Inc. maintains a healthy 18.05% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Quince Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Quince Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Quince Therapeutics, Inc. (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Quince Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.20% | $34.57 Million | $114.48 Million | +0.06pp |
| 2023-12-31 | 30.14% | $54.31 Million | $180.20 Million | -13.75pp |
| 2022-12-31 | 43.89% | $45.60 Million | $103.91 Million | +16.06pp |
| 2021-12-31 | 27.83% | $37.08 Million | $133.23 Million | -7.52pp |
| 2020-12-31 | 35.35% | $66.98 Million | $189.47 Million | -3.77pp |
| 2019-12-31 | 39.12% | $48.65 Million | $124.37 Million | -25.16pp |
| 2018-12-31 | 64.28% | $46.84 Million | $72.88 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more